Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 513% % 27%
Return On Equity -25% % 56%
Return On Assets -22% % 54%
Operating Margin -127% % 96%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,925,314 shares 45%
Common Stock, Shares, Outstanding 3,695,158 shares 46%
Entity Public Float $4,800,000 USD -32%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 3,225,000 shares 28%
Weighted Average Number of Shares Outstanding, Diluted 3,225,000 shares 28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,855,000 USD 1372%
Research and Development Expense $496,000 USD 95%
General and Administrative Expense $5,992,000 USD 2.1%
Operating Income (Loss) $3,633,000 USD 39%
Nonoperating Income (Expense) $1,434,000 USD 123%
Net Income (Loss) Attributable to Parent $2,199,000 USD 58%
Earnings Per Share, Basic 0 USD/shares 58%
Earnings Per Share, Diluted 0 USD/shares 46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,568,000 USD 59%
Accounts Receivable, after Allowance for Credit Loss, Current $100,000 USD 127%
Other Assets, Current $11,000 USD 0%
Assets, Current $5,065,000 USD 43%
Other Long-term Investments $5,350,000 USD 0%
Property, Plant and Equipment, Net $0 USD
Assets $10,415,000 USD 17%
Accounts Payable, Current $480,000 USD 58%
Employee-related Liabilities, Current $100,000 USD
Liabilities, Current $877,000 USD 25%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD
Retained Earnings (Accumulated Deficit) $270,221,000 USD -0.82%
Stockholders' Equity Attributable to Parent $9,538,000 USD 16%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $9,538,000 USD 16%
Liabilities and Equity $10,415,000 USD 17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $968,000 USD 48%
Net Cash Provided by (Used in) Financing Activities $1,375,000 USD
Common Stock, Shares Authorized 400,000,000 shares 1900%
Common Stock, Shares, Issued 3,814,260 shares 41%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $407,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,568,000 USD 59%
Deferred Tax Assets, Valuation Allowance $83,156,000 USD 0.87%
Deferred Tax Assets, Gross $83,156,000 USD 0.87%
Property, Plant and Equipment, Gross $126,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $53,281,000 USD 9.8%
Preferred Stock, Shares Authorized 100,000,000 shares 19900%
Unrecognized Tax Benefits $0 USD
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $468,000 USD -23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares